James McArthur, PhD Archives - CureDuchenne

Title: President and Chief Executive Officer

Organization: PepGen

Bio: James has 25+ years of industry experience, has cofounded 5 biotechnology companies, 3 of which were acquired and been a director of two companies that went public. He was founding CEO of Imara, a public company developing therapies for sickle cell disease and b-thallasemia, co-founder and President of R&D of Cydan a rare disease accelerator and founding CSO of Synovex/Adheron, a rheumatology therapy company acquired by Roche. Prior to these companies, James held senior research leadership roles in several pioneering gene and stem cell therapy companies. He is a Venture Partner at RA Capital and was an entrepreneur in residence at HealthCare Ventures. James was a post-doctoral fellow at MIT and UC Berkeley working with Drs. David Raulet and Nobel Laureate James Allison, before which, he received his PhD in molecular oncology and BSc in biochemistry from McGill University in Montreal

2021 FUTURES: Exon Skipping Panel

Information and updates on exon skipping therapies and research from experts in the Duchenne community.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Kevin Eggan, PhD

Group Vice President, Head of Research and Early Development

BioMarin

See more from same speaker

Leslie Magnus, MD

Vice President, Medical Affairs

NS Pharma

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Exon Skipping and Read Through Agents Panel

A brief introduction on the rationale behind mechanisms of endogenous dystrophin restoration, like exon skipping and read through agent therapies, followed by critical information and updates from the companies in this space. Moderated discussion included.

Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

See more from same speaker

Jay Chauhan, PharmD

Medical Science Liaison

NS Pharma

See more from same speaker

Brett Crawford, PhD

Executive Director and Head of the Musculoskeletal Therapeutic Area

BioMarin Pharmaceutical Inc.

See more from same speaker

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Xiao Shelley Hu, PhD, MS

VP

Wave Life Sciences

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker